Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel hydroxypropyl-beta-cyclodextrin formulation
- Development stage
- Phase 3
- Lead developer
- SK Chemicals
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
SID530 is a novel **parenteral formulation of docetaxel** that contains hydroxypropyl-beta-cyclodextrin (HP-β-CD) as a solubilizing agent. This formulation was developed to be comparable to Taxotere, the original docetaxel formulation, in terms of pharmacokinetics and is administered intravenously. Comparative studies in nonhuman primates show that SID530 achieves **bioequivalence with Taxotere** based on similar pharmacokinetic parameters (Cmax, Tmax, AUC), indicating comparable distribution and plasma profile. The inclusion of hydroxypropyl-beta-cyclodextrin is aimed at improving the solubility and potentially reducing formulation-related toxicities typical of polysorbate 80-based docetaxel products[1].
- Brand names
- SID530SID-530SID 530
- Other names
- SID530SID-530SID 530
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel hydroxypropyl-beta-cyclodextrin formulation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel hydroxypropyl-beta-cyclodextrin formulation.